Smooth Drug Development December 2024 News Release

Monthly News – December 2024

We are excited to share the first updates of 2025, showcasing the progress and new developments at Smooth Drug Development this January.

New Projects

Our portfolio continues to grow with these promising initiatives:

• Medical Writing Services: Signing two contracts for bioequivalence studies with Semaglutide.
• Bioequivalence Study: Signing a contract for a study with Eltrombopag.

Clinical and Scientific Departments News:

Significant advancements were achieved across various trials:

• Trametinib Trial: CTA submission successfully performed.
• Pembrolizumab Trial: Reached a milestone with 78 patients enrolled.
• Eculizumab Trial: Submitted the interim report for a half-year treatment.

Business Development News:

Our Business Development team conducted several client visits, fostering stronger relationships and exploring new opportunities for collaboration.

As we embark on 2025, we thank our clients, partners, and team members for their continued support. We are looking forward to achieving even greater success together!